JAN 16, 2019 09:00 AM PST

Predicting Response to Intravesical Immunotherapy with BCG

SPONSORED BY: Abbott Molecular
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Professor of Urology and Director of Urologic Oncology Fellowship, M.D. Anderson Cancer Center
    Biography
      Dr Ashish M. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at M.D. Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr Kamat's expertise is in multidisciplinary management of urologic cancers with an emphasis bladder and prostate cancer, organ sparing therapies, minimally invasive techniques, and orthotopic bladder substitution (neobladder). While he is a busy surgeon, he maintains an active research portfolio to improve the care of patients. Dr Kamat's efforts are directed towards identifying predictors of response to therapy - especially immunotherapy - as a first step towards personalized cancer therapeutics. A major focus of his laboratory research is to develop novel treatments for bladder cancer and identify resistance mechanisms and ways to overcome them. He serves as project PI on the MD Anderson Cancer Center GU (Bladder) SPORE. He has authored over 200 publications, editorials & book chapters in prestigious journals; he is listed in'Who's Who in Medicine' and 'Best Doctors in America' and has won the Compassionate Doctor Award from patient groups. He is an exceptional educator nominated twice for the Robert M. Chamberlain Distinguished Mentor Award and has been invited as a visiting professor to several universities across the world. Dr Kamat is also Co President,International Bladder Cancer Network, Chair, Bladder Cancer Think Tank (2015), Chair, Bladder Cancer Task Force for SITC, actively participates in various global urologic efforts, and serves on the board of regional and national societies for Urology.

    Abstract:

    DATE: January 16th, 2019

    TIME: 9:00AM PST, 12:00PM EST

    Dr. Kamat will present his clinical experience using molecular markers, in addition to the standard of care, to examine patient outcomes in the BCG response monitoring scenario.

    Learning Objectives:

    • Review of Bladder Cancer case studies to understand the use of BCG in bladder cancer subtypes
    • Understand BCG tolerance, patient response, and use of UroVysion

    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    NOV 18, 2019 07:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    MAY 23, 2019 09:00 AM PDT
    C.E. CREDITS
    MAY 23, 2019 09:00 AM PDT
    DATE:  May 23, 2019TIME:   9:00am PDT, 12:00pm EDT Although mesenchymal stem/stromal cells (MSCs) chondrogenic differentiation has been thoroughly investigated...
    Loading Comments...
    Show Resources